Analyst Price Targets — ALGS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 21, 2026 10:32 am | — | Cantor Fitzgerald | $20.00 | $5.60 | TheFly | Aligos Therapeutics initiated with an Overweight at Cantor Fitzgerald |
| January 7, 2026 5:38 am | Michael Yee | UBS | $20.00 | $8.76 | StreetInsider | UBS Starts Aligos Therapeutics Inc. (ALGS) at Buy |
| January 6, 2023 9:01 am | — | Piper Sandler | $3.00 | $1.22 | Benzinga | Piper Sandler Upgrades Aligos Therapeutics to Overweight, Raises Price Target to $3 |
| January 6, 2023 5:24 am | — | Jefferies | $3.00 | $0.99 | Benzinga | Jefferies Upgrades Aligos Therapeutics to Buy, Raises Price Target to $3 |
Latest News for ALGS
Bank of America Corp DE grew its holdings in shares of Aligos Therapeutics, Inc. (NASDAQ: ALGS) by 1,652.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 229,754 shares of the company's stock after buying an additional 216,646 shares
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Cantor Global Healthcare Conference.
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing has been initiated in the Phase 1 study of ALG-170675, an investigational next-generation antisense oligonucleotide (ASO) being evaluated for…
SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company's second quarter 2026 financial results on Thursday, August 6, 2026, before the open of the U.S. financial markets.
SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has completed enrollment of both the HBeAg+ (Part 1a) and HBeAg- (Part 2a) participants in the Phase 2 B-SUPREME study of pevifoscorvir…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALGS.
U.S. House Trading
No House trades found for ALGS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.